Intellia Therapeutics, Inc. (NTLA) Expected to Announce Earnings of -$0.49 Per Share
Equities analysts predict that Intellia Therapeutics, Inc. (NASDAQ:NTLA) will post earnings of ($0.49) per share for the current quarter, Zacks reports. Four analysts have issued estimates for Intellia Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.54) and the highest estimate coming in at ($0.43). Intellia Therapeutics reported earnings of ($0.22) per share during the same quarter last year, which indicates a negative year over year growth rate of 122.7%. The firm is scheduled to issue its next earnings report on Tuesday, November 7th.
According to Zacks, analysts expect that Intellia Therapeutics will report full year earnings of ($1.73) per share for the current year, with EPS estimates ranging from ($1.99) to ($1.49). For the next year, analysts anticipate that the company will post earnings of ($1.97) per share, with EPS estimates ranging from ($2.52) to ($1.43). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.03). Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The business had revenue of $5.90 million during the quarter, compared to analyst estimates of $5.83 million. The firm’s revenue for the quarter was up 40.5% compared to the same quarter last year.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Cann reaffirmed a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, August 1st. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 target price (up from $19.00) on shares of Intellia Therapeutics in a report on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 target price on shares of Intellia Therapeutics in a report on Tuesday, October 3rd. Finally, TheStreet raised Intellia Therapeutics from a “d+” rating to a “c-” rating in a report on Thursday, July 6th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $26.80.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/11/intellia-therapeutics-inc-ntla-expected-to-announce-earnings-of-0-49-per-share.html.
Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Intellia Therapeutics in the second quarter worth $101,000. Nisa Investment Advisors LLC bought a new position in Intellia Therapeutics in the second quarter valued at $134,000. Bank of Montreal Can increased its stake in Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after acquiring an additional 7,222 shares during the last quarter. Nationwide Fund Advisors increased its stake in Intellia Therapeutics by 117.7% in the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after acquiring an additional 4,351 shares during the last quarter. Finally, IHT Wealth Management LLC bought a new position in Intellia Therapeutics in the first quarter valued at $117,000. 46.52% of the stock is currently owned by hedge funds and other institutional investors.
Intellia Therapeutics (NASDAQ:NTLA) traded down 0.85% during mid-day trading on Wednesday, hitting $29.20. The stock had a trading volume of 198,517 shares. Intellia Therapeutics has a 1-year low of $10.83 and a 1-year high of $31.90. The stock’s market cap is $1.05 billion. The firm’s 50-day moving average price is $25.32 and its 200-day moving average price is $25.32.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.